Drugs / S-309309
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06106334 | Nov → Dec 2023 | obesity disorder | Shionogi | Completed | No outcome recorded |
| Phase 1 | NCT05247970 | Jan → Oct 2022 | obesity disorder | Shionogi | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05925114 | Jun 2023 → Apr 2024 | obesity disorder | Shionogi | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | S-309309 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05247970 ↗ |
| Action | Inhibit | “S-309309 is a novel oral inhibitor of monoacylglycerol O-acyltransferase 2” PMID 39832041 ↗ Jan 2025 |
| Route | Oral | “Administered as oral capsules” NCT05925114 ↗ |